Table 2.
NFLD without DH (N = 14) | NFLD with DH (N = 18) | P value* | |||
---|---|---|---|---|---|
Mean ± SD | (Range) | Mean ± SD | (Range) | ||
Age-baseline (years) | 55.1 ± 9.1 | (38–73) | 52.8 ± 9.8 | (38–73) | 0.18 |
Mean IOP (mmHg) | 13.9 ± 2.9 | (9.9–20.3) | 13.7 ± 2.6 | (9.9–19.0) | 0.99 |
Axial length (mm) | 25.1 ± 1.3 | (22.9–27.0) | 24.9 ± 1.2 | (22.9–27.0) | 0.48 |
Central corneal thickness (μm) | 523.0 ± 39.6 | (436–583) | 523.0 ± 39.6 | (467–581) | 0.77 |
Visual field mean deviation (dB) | − 4.4 ± 3.8 | (− 13.1 to − 0.22) | − 3.2 ± 1.9 | (− 7.89 to 0.35) | 0.31 |
Medication-baseline | 1.5 ± 1.5 | (0–4) | 1.6 ± 1.2 | (0–4) | 0.72 |
Medication-at last | 1.9 ± 1.3 | (0–4) | 2.6 ± 1.0 | (1–4) | 0.48 |
OCTA follow-up period (month) | 20.6 ± 5.6 | (12–25) | 22.6 ± 5.3 | (12–28) | > 0.99 |
The frequency of OCTA exam | 4.3 ± 1.2 | (3–6) | 4.2 ± 1.1 | (3–6) | > 0.99 |
CMvD (+ /−), no | 4/10 | 10/8 | 0.14 | ||
NFLD location (superotemporal/inferotemporal), no | 7/7 | 6/12 | 0.36 | ||
deMv-angle-baseline (°) | 32.9 ± 12.6 | (12.7–54.6) | 30.8 ± 12.7 | (5.3–50.9) | 0.65 |
deMv-angle-final (°) | 34.3 ± 14.9 | (11.1–60.3) | 40.8 ± 13.4 | (13.6–66.4) | 0.20 |
VD-baseline (%) | 54.3 ± 7.0 | (42.4–63.0) | 54.8 ± 5.5 | (39.2–61.2) | > 0.99 |
VD-final (%) | 55.9 ± 7.1 | (47.5–67.4) | 53.0 ± 6.8 | (39.2–59.8) | 0.24 |
NFLD angle-baseline (°) | 17.4 ± 14.3 | (5.2–52.7) | 20.7 ± 13.3 | (0–45.1) | 0.51 |
NFLD angle-final (°) | 18.9 ± 15.3 | (5.9–54.9) | 23.9 ± 11.6 | (7.0–48.7) | 0.30 |
Data are presented as mean ± standard deviation (SD) with the minimum and maximum values in parentheses.
CMvD peripapillary choroidal microvasculature dropout, deMv decreased superficial retinal microvasculature, DH disc hemorrhage, IOP intraocular pressure, NFLD nerve fiber layer defect, OCTA optical coherence tomography angiography, VD vessel density.
*Analyzed using linear mixed-effect modeling between NFLD without DH and NFLD with DH.